Markus Kuksis1, Yizhuo Gao2, William Tran3,4, Christianne Hoey3, Alex Kiss3, Adam S Komorowski5, Aman J Dhaliwal2, Arjun Sahgal3,4, Sunit Das6, Kelvin K Chan7,8, Katarzyna J Jerzak3,7. 1. Department of Medicine, Queen's University, Kingston, Ontario, Canada. 2. Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. 3. Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. 4. Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. 5. Division of Medical Microbiology, McMaster University, Hamilton, Ontario, Canada. 6. Division of Neurosurgery, St. Michael's Hospital, Toronto, Ontario, Canada. 7. Division of Medical Oncology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. 8. The Canadian Centre for Applied Research in Cancer Control, Vancouver, British Columbia, Canada.
Abstract
BACKGROUND: Patients with metastatic breast cancer (MBC) are living longer, but the development of brain metastases often limits their survival. We conducted a systematic review and meta-analysis to determine the incidence of brain metastases in this patient population. METHODS: Articles published from January 2000 to January 2020 were compiled from four databases using search terms related to breast cancer, brain metastasis, and incidence. The overall and per patient-year incidence of brain metastases were extracted from studies including patients with human epidermal growth factor receptor-2 positive (HER2+), triple negative, and hormone receptor (HR)+/hormone receptor negative (HER2-) MBC; pooled overall estimates for incidence were calculated using random effects models. RESULTS: 937 articles were compiled, and 25 were included in the meta-analysis. Incidence of brain metastases in patients with HER2+ MBC, triple negative MBC, and HR+/HER2- MBC was reported in 17, 6, and 4 studies, respectively. The pooled cumulative incidence of brain metastases was 31% for the HER2+ subgroup (median follow-up: 30.7 months, IQR: 24.0-34.0), 32% for the triple negative subgroup (median follow-up: 32.8 months, IQR: 18.5-40.6), and 15% among patients with HR+/HER2- MBC (median follow-up: 33.0 months, IQR: 31.9-36.2). The corresponding incidences per patient-year were 0.13 (95% CI: 0.10-0.16) for the HER2+ subgroup, 0.13 (95%CI: 0.09-0.20) for the triple negative subgroup, and only 0.05 (95%CI: 0.03-0.08) for patients with HR+/HER2- MBC. CONCLUSION: There is a high incidence of brain metastases among patients with HER2+ and triple negative MBC. The utility of a brain metastases screening program warrants investigation in these populations.
BACKGROUND: Patients with metastatic breast cancer (MBC) are living longer, but the development of brain metastases often limits their survival. We conducted a systematic review and meta-analysis to determine the incidence of brain metastases in this patient population. METHODS: Articles published from January 2000 to January 2020 were compiled from four databases using search terms related to breast cancer, brain metastasis, and incidence. The overall and per patient-year incidence of brain metastases were extracted from studies including patients with human epidermal growth factor receptor-2 positive (HER2+), triple negative, and hormone receptor (HR)+/hormone receptor negative (HER2-) MBC; pooled overall estimates for incidence were calculated using random effects models. RESULTS: 937 articles were compiled, and 25 were included in the meta-analysis. Incidence of brain metastases in patients with HER2+ MBC, triple negative MBC, and HR+/HER2- MBC was reported in 17, 6, and 4 studies, respectively. The pooled cumulative incidence of brain metastases was 31% for the HER2+ subgroup (median follow-up: 30.7 months, IQR: 24.0-34.0), 32% for the triple negative subgroup (median follow-up: 32.8 months, IQR: 18.5-40.6), and 15% among patients with HR+/HER2- MBC (median follow-up: 33.0 months, IQR: 31.9-36.2). The corresponding incidences per patient-year were 0.13 (95% CI: 0.10-0.16) for the HER2+ subgroup, 0.13 (95%CI: 0.09-0.20) for the triple negative subgroup, and only 0.05 (95%CI: 0.03-0.08) for patients with HR+/HER2- MBC. CONCLUSION: There is a high incidence of brain metastases among patients with HER2+ and triple negative MBC. The utility of a brain metastases screening program warrants investigation in these populations.
Authors: Jennifer K Litton; Hope S Rugo; Johannes Ettl; Sara A Hurvitz; Anthony Gonçalves; Kyung-Hun Lee; Louis Fehrenbacher; Rinat Yerushalmi; Lida A Mina; Miguel Martin; Henri Roché; Young-Hyuck Im; Ruben G W Quek; Denka Markova; Iulia C Tudor; Alison L Hannah; Wolfgang Eiermann; Joanne L Blum Journal: N Engl J Med Date: 2018-08-15 Impact factor: 91.245
Authors: Adam M Brufsky; Musa Mayer; Hope S Rugo; Peter A Kaufman; Elizabeth Tan-Chiu; Debu Tripathy; Iulia Cristina Tudor; Lisa I Wang; Melissa G Brammer; Mona Shing; Marianne Ulcickas Yood; Denise A Yardley Journal: Clin Cancer Res Date: 2011-07-15 Impact factor: 12.531
Authors: Elisabeth Bergen; Anna S Berghoff; Margaretha Rudas; Peter Dubsky; Catharina De Vries; Claudia Sattlberger; Robert M Mader; Flora Zagouri; Cornelia Sparber; Florian Fitzal; Michael Gnant; Andrea Rottenfusser; Christoph C Zielinski; Matthias Preusser; Guenther G Steger; Rupert Bartsch Journal: Breast Care (Basel) Date: 2014-10 Impact factor: 2.860
Authors: Thomas Yau; Charles Swanton; Sue Chua; Ashley Sue; Geraldine Walsh; A Rostom; Stephen R Johnston; Mary E R O'Brien; Ian E Smith Journal: Acta Oncol Date: 2006 Impact factor: 4.089
Authors: Rupert Bartsch; Catharina De Vries; Ursula Pluschnig; Peter Dubsky; Zsuzsanna Bago-Horvath; Simon P Gampenrieder; Margaretha Rudas; Robert M Mader; Andrea Rottenfusser; Christoph Wiltschke; Michael Gnant; Christoph C Zielinski; Guenther G Steger Journal: BMC Cancer Date: 2009-10-17 Impact factor: 4.430
Authors: Yizhuo Kelly Gao; Markus Kuksis; Badr Id Said; Rania Chehade; Alex Kiss; William Tran; Faisal Sickandar; Arjun Sahgal; Ellen Warner; Hany Soliman; Katarzyna J Jerzak Journal: Oncologist Date: 2021-09-21